InscoBio "Full-Scale Development of Natural Product-Based Diabetes and Anticancer Drugs"
[Asia Economy Reporter Hyunseok Yoo] InsKobi announced on the 1st that InsGen, a subsidiary of Apimez, has signed a technology transfer agreement with the Korea Atomic Energy Research Institute for the ‘technology for developing diabetes and anticancer drugs using bio and food/pharmaceutical materials.’
Apimez established InsGen INC, a subsidiary for natural health functional foods and new drug development, and InsGen received the technology transfer from the Korea Atomic Energy Research Institute. To promote future research outcomes and commercialization, Korea Science and Technology Holdings, which was funded by capital contributions from 17 government-funded research institutes, also plans to make additional investments in InsGen.
The technology transferred to InsGen from the Korea Atomic Energy Research Institute is for developing diabetes and anticancer drugs using natural substances such as bio and food/pharmaceutical materials. This technology was developed through the Korea Atomic Energy Research Institute’s own R&D projects and national research and development support projects. Two international SCI-level papers and three patent registrations have already been completed, and animal experiments have demonstrated excellent anti-diabetic effects (with multi-target potential) and over 95% anticancer efficacy.
Based on this technology, InsGen plans to enter the natural health functional food market and develop exclusive natural new drugs through subsequent clinical trials. It is expected that they will be able to enter the diabetes treatment and anticancer drug markets based on high value-added new drug development in the future.
An InsKobi official explained, “Apimez, which has experience in researching and developing Apitoxin, the first domestic natural new drug, is expected to greatly assist InsGen’s development of natural drug candidates for diabetes and anticancer treatments.” He added, “Additionally, based on the DDS (drug delivery system) technology accumulated through formulation technology business, it is expected to positively impact the quality of new drugs and health functional foods developed by InsGen.”
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "One Comment Could Lead to a Report": 86% of Elementary Teachers Feel Anxious; Half Consider Resignation or Career Change
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
He continued, “InsKobi’s bio affiliates are achieving visible results in each bio field, so we expect to grow substantially as a bio meditech platform.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
